RLAY vs. RXRX

In the year-to-date period, RLAY achieves a 13.11% return, which is significantly higher than RXRX's 1.78% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Relay Therapeutics, Inc. (RLAY) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RLAY Sharpe Ratio is -0.63, which is lower than the RXRX Sharpe Ratio of -0.35. The chart below compares the historical Sharpe Ratios of RLAY and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither RLAY nor RXRX has paid dividends to shareholders.

The maximum RLAY drawdown since its inception was -93.81%, which is greater than RXRX's maximum drawdown of -88.97%. Use the drawdown chart below to compare losses from any high point for RLAY and RXRX. For additional features, visit the drawdowns tool.

Relay Therapeutics, Inc. (RLAY) and Recursion Pharmaceuticals, Inc. (RXRX) have volatilities of 28.18% and 29.02%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Relay Therapeutics, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.